gla 27 has been researched along with lipid a in 10 studies
| Studies (gla 27) | Trials (gla 27) | Recent Studies (post-2010) (gla 27) | Studies (lipid a) | Trials (lipid a) | Recent Studies (post-2010) (lipid a) |
|---|---|---|---|---|---|
| 11 | 0 | 2 | 3,901 | 125 | 1,143 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (70.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, A; Homma, JY; Ikeda, S; Kiso, M; Kumazawa, Y; Matsuura, M; Nakatsuka, M; Nishimura, C | 1 |
| Hasegawa, A; Homma, JY; Ikeda, S; Kiso, M; Kumazawa, Y; Nakatsuka, M; Nishimura, C; Sai, K; Yamamoto, A | 1 |
| Hasegawa, A; Homma, JY; Kiso, M; Kumazawa, Y; Ogawa, Y; Takimoto, H; Yamamoto, A | 1 |
| Hasegawa, A; Homma, JY; Ikeda, S; Kiso, M; Kumazawa, Y; Nakatsuka, M; Nishimura, C; Yamamoto, A | 1 |
| Furuya, T; Homma, Y; Inada, K; Kiso, M; Kumazawa, Y; Nagumo, T; Nakatsuka, M; Takimoto, H; Yamamoto, A; Yoshida, M | 1 |
| Hasegawa, A; Homma, JY; Kiso, M; Kojima, Y; Kumazawa, Y; Matsuura, M; Yamamoto, A | 1 |
| Hasegawa, A; Homma, JY; Ikeda, S; Kiso, M; Kumazawa, Y; Nakatsuka, M; Nishimura, C; Takimoto, H; Yamamoto, A | 1 |
| Fujishima, Y; Hasegawa, A; Kiso, M; Ogawa, Y; Tanahashi, M; Tanaka, S | 1 |
| Bozzacco, L; Brane, L; Cheong, C; Dandamudi, D; Longhi, MP; Mehandru, S; Pantel, A; Ruane, D; Shrestha, E; Steinman, RM; Teixeira, A | 1 |
| Beaune, G; Brochard-Wyart, F; Cochet-Escartin, O; Cuvelier, D; Dufour, S; Garcia, S; Gurchenkov, VV; Khalifat, N; Murrell, MP; Stirbat, TV | 1 |
10 other study(ies) available for gla 27 and lipid a
| Article | Year |
|---|---|
Enhancement of nonspecific resistance to microbial infections of synthetic lipid A-subunit analogues of GLA-27 modified at the C1 position of the glucosamine backbone.
Topics: Animals; Female; Immunity, Innate; Interferons; Killer Cells, Natural; Lipid A; Mice; Mice, Inbred ICR; Pseudomonas Infections; Structure-Activity Relationship; Vaccinia | 1990 |
Immunopharmacological activities of chemically synthesized lipid A-subunit analogue GLA-27 combined with muramyl dipeptide via spacers of different carbon chain length.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antiviral Agents; Female; Immunity; Immunity, Innate; Interferons; Killer Cells, Natural; Lipid A; Macrophage Activation; Mice; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 1988 |
Effect of chemical modification at C1 of the glucosamine backbone of lipid A-subunit analog GLA-27 on manifestation of immunopharmacological activity.
Topics: Animals; Cell Division; Cells, Cultured; DNA Replication; Glucosamine; Lipid A; Mice; Mice, Inbred C3H; Mitogens; Structure-Activity Relationship; Thymidine; Tumor Necrosis Factor-alpha | 1988 |
Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antiviral Agents; Drug Evaluation, Preclinical; Lipid A; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pseudomonas Infections; Vaccinia | 1988 |
Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity.
Topics: Adjuvants, Immunologic; Animals; Colony-Stimulating Factors; Female; Lipid A; Lymphocyte Activation; Macrophage Activation; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Pyrogens; Rabbits; Shwartzman Phenomenon; Tumor Necrosis Factor-alpha | 1988 |
Effects of backbone structures and stereospecificities of lipid A-subunit analogues on their biological activities.
Topics: Animals; B-Lymphocytes; Glycoproteins; Interferon Inducers; Lipid A; Lymphocyte Activation; Mice; Mice, Inbred C3H; Mitogens; Rabbits; Spleen; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 1986 |
Effect of stereospecificity of chemically synthesized lipid A-subunit analogues GLA-27 and GLA-40 on the expression of immunopharmacological activities.
Topics: Animals; Antibody Formation; B-Lymphocytes; Cell Division; Glycoproteins; Lipid A; Lymphocyte Activation; Lysosomes; Macrophage Activation; Mice; Phagocytosis; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Viral Interference | 1987 |
Synthesis of 2-deoxy-4-O-phosphono-3-O-tetradecanoyl-2-[(3R)- and (3S)-3-tetradecanoyloxytetradecanamido]-D-glucose: a diastereoisomeric pair of 4-O-phosphono-D-glucosamine derivatives (GLA-27) related to bacterial lipid A.
Topics: Indicators and Reagents; Lipid A; Magnetic Resonance Spectroscopy; Optical Rotation; Stereoisomerism | 1986 |
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Viral; Dendritic Cells; HIV; HIV Core Protein p24; Lipid A; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Mice, Knockout; Specific Pathogen-Free Organisms; Toll-Like Receptor 4; Vaccines, Subunit | 2012 |
How cells flow in the spreading of cellular aggregates.
Topics: Acrylic Resins; Adhesives; Animals; Cadherins; Cell Adhesion; Cell Communication; Cell Line, Tumor; Cell Movement; Disease Progression; Friction; Green Fluorescent Proteins; Lipid A; Luminescent Proteins; Mechanotransduction, Cellular; Mice; Microscopy, Confocal; Models, Biological; Red Fluorescent Protein; Sarcoma; Wetting Agents | 2014 |